Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Mol Pain ; 11: 6, 2015 Feb 12.
Artigo em Inglês | MEDLINE | ID: mdl-25889021

RESUMO

BACKGROUND: The G-protein-coupled receptor 40 (GPR40) is suggested to function as a transmembrane receptor for medium- to long-chain free fatty acids and is implicated to play a role in free fatty acids-mediated enhancement of glucose-stimulated insulin secretion from pancreas. However, the functional role of GPR40 in nervous system including somatosensory pain signaling has not been fully examined yet. RESULTS: Intrathecal injection of GPR40 agonist (MEDICA16 or GW9508) dose-dependently reduced ipsilateral mechanical allodynia in CFA and SNL models and thermal hyperalgesia in carrageenan model. These anti-allodynic and anti-hyperalgesic effects were almost completely reversed by a GPR40 antagonist, GW1100. Immunohistochemical analysis revealed that GPR40 is expressed in spinal dorsal horn and dorsal root ganglion neurons, and immunoblot analysis showed that carrageenan or CFA inflammation or spinal nerve injury resulted in increased expression of GPR40 in these areas. Patch-clamp recordings from spinal cord slices exhibited that bath-application of either MEDICA16 or GW9508 significantly decreased the frequency of spontaneous excitatory postsynaptic currents in the substantia gelatinosa neurons of the three pain models. CONCLUSIONS: Our results indicate that GPR40 signaling pathway plays an important suppressive role in spinal nociceptive processing after inflammation or nerve injury, and that GPR40 agonists might serve as a new class of analgesics for treating inflammatory and neuropathic pain.


Assuntos
Ácidos Graxos não Esterificados/metabolismo , Neuralgia/metabolismo , Receptores Acoplados a Proteínas G/metabolismo , Analgésicos/farmacologia , Animais , Comportamento Animal , Modelos Animais de Doenças , Potenciais Pós-Sinápticos Excitadores/efeitos dos fármacos , Gânglios Espinais/metabolismo , Inflamação/tratamento farmacológico , Masculino , Metilaminas/farmacologia , Camundongos Endogâmicos C57BL , Neuralgia/tratamento farmacológico , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Propionatos/farmacologia , Nervos Espinhais/efeitos dos fármacos , Nervos Espinhais/metabolismo
2.
Mol Pain ; 10: 17, 2014 Mar 10.
Artigo em Inglês | MEDLINE | ID: mdl-24612480

RESUMO

BACKGROUND: The phylogenetically highly conserved CK1 protein kinases consisting of at least seven isoforms form a distinct family within the eukaryotic protein kinases. CK1 family members play crucial roles in a wide range of signaling activities. However, the functional role of CK1 in somatosensory pain signaling has not yet been fully understood. The aim of this study was to clarify the role of CK1 in the regulation of inflammatory pain in mouse carrageenan and complete Freund's adjuvant (CFA) models. RESULTS: We have used two structurally different CK1 inhibitors, TG003 and IC261. TG003, which was originally identified as a cdc2-like kinase inhibitor, had potent inhibitory effects on CK1 isoforms in vitro and in cultured cells. Intrathecal injection of either TG003 (1-100 pmol) or IC261 (0.1-1 nmol) dose-dependently decreased mechanical allodynia and thermal hyperalgesia induced by carrageenan or CFA. Bath-application of either TG003 (1 µM) or IC261 (1 µM) had only marginal effects on spontaneous excitatory postsynaptic currents (sEPSCs) recorded in the substantia gelatinosa neurons of control mice. However, both compounds decreased the frequency of sEPSCs in both inflammatory pain models. CONCLUSIONS: These results suggest that CK1 plays an important pathophysiological role in spinal inflammatory pain transmission, and that inhibition of the CK1 activity may provide a novel strategy for the treatment of inflammatory pain.


Assuntos
Inibidores Enzimáticos/farmacologia , Hiperalgesia/tratamento farmacológico , Indóis/farmacologia , Limiar da Dor/efeitos dos fármacos , Dor/tratamento farmacológico , Floroglucinol/análogos & derivados , Tiazóis/farmacologia , Animais , Carragenina/toxicidade , Caseína Quinase I/antagonistas & inibidores , Caseína Quinase I/genética , Caseína Quinase I/metabolismo , Células Cultivadas , Modelos Animais de Doenças , Inibidores Enzimáticos/uso terapêutico , Potenciais Pós-Sinápticos Excitadores/efeitos dos fármacos , Potenciais Pós-Sinápticos Excitadores/genética , Humanos , Hiperalgesia/fisiopatologia , Indóis/uso terapêutico , Inflamação/induzido quimicamente , Inflamação/complicações , Masculino , Potenciais da Membrana/efeitos dos fármacos , Potenciais da Membrana/genética , Camundongos , Camundongos Endogâmicos C57BL , Dor/etiologia , Dor/patologia , Medição da Dor , Floroglucinol/farmacologia , Floroglucinol/uso terapêutico , Transporte Proteico/efeitos dos fármacos , Medula Espinal/patologia , Tiazóis/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...